FDA Clears Pathwork Diagnostics' Tissue-of-Origin Test for Use with FFPE Samples
June 15, 2010
FDA Clears Pathwork Diagnostics' Tissue-of-Origin Test for Use with FFPE Samples
The FDA originally cleared the Affymetrix-manufactured test in 2008 for use with frozen tissue samples, and Pathwork has been offering the TOO assay with FFPE samples as a lab-developed test since 2009.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Pathwork's Economics Study Finds TOO Test 'Strongly' Cost-Effective in Extending Survival
January 18, 2012 / Pharmacogenomics Reporter - FDA Clears Affymetrix Gene Expression Reagents for IVD Use
May 10, 2011 / BioArray News - Despite Years of Development, Affymetrix's Dx Partners Slow to Bring Tests to Market
March 15, 2011 / BioArray News - In 2010, Array Makers Saw CGH Become the Standard in Cytogenetics, Prepared for Next Wave of GWAS
January 4, 2011 / BioArray News - Pathwork Diagnostics Closes $30M Series C Round, Plans Investments in Sales Team, New Tests
October 12, 2010 / BioArray News